
    
      -  To compare overall Survival(OS) between the patients added Goserelin(ZOLADEXTM) to
           Tamoxifen and the patients treated with Tamoxifen alone in premenopausal status

        -  To compare 5-year disease free survival rate (DFS rate) between the patients who took
           tamoxifen only in postmenopause and the patients added Goserelin(ZOLADEXTM) to Tamoxifen
           for inducing ovarian function suppression in premenopause

        -  To determine the tolerability and safety of Tamoxifen with or without concomitant
           Zoladex
    
  